De-escalation of DAPT—A Potential Strategy for Treating Ticagrelor-Related Dyspnea?

Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction

The incidence of dyspnea and causal relationship to treatment with ticagrelor has been a matter of debate since phase 2 and 3 trials and the launch of ticagrelor. In a previous review, Cattaneo and Faioni[1] elucidated on potential mechanisms and suggested that inhibition of P2Y12 on C fibers of sensory neurons mainly accounts for the observed incidence of dyspnea which is not related to the antiplatelet effects but likely explained by differences in pharmacokinetic properties of P2Y12 inhibitors. In addition, reduced cellular uptake and metabolism of adenosine by inhibiting the sodium-independent equilibrate nucleoside transporter (ENT1) has been discussed as other mechanism.[2]

In the landmark phase-3 PLATO trial, most dyspnea episodes were mild or moderate and occurred at a rate of 14.5% in ticagrelor-treated patients compared with 8.7% in clopidogrel patients. Severe dyspnea episodes were reported very rarely and at similar rates in both treatment groups, although these episodes did not alter the efficacy or safety of ticagrelor treatment compared with clopidogrel.[3]

The incidence of ticagrelor discontinuation related to dyspnea varies suggesting that it depends on patient characteristics and probably education. Ticagrelor discontinuation because of dyspnea was only 0.9% in the PLATO trial, whereas it was reported in 6 to 10% of cases and tended to occur earlier rather than late after drug initiation and percutaneous coronary intervention (PCI) in the TWILIGHT trial investigating ticagrelor monotherapy.[4] Independent predictors include ethnic background with lower incidence in Asian population, smoking, prior PCI, hypercholesterolemia, prior coronary artery bypass, peripheral artery disease, obesity, and older age in the TWILIGHT study.[4]

In this issue of the journal, Kim et al[5] investigated the clinical impact of dyspnea in a larger dataset of Asian patients enrolled in the TALOS-AMI study, a randomized trial investigating the effects of unguided de-escalation from ticagrelor to clopidogrel 1 month after acute myocardial infarction (AMI) and initial dual antiplatelet therapy (DAPT) with ticagrelor. Dyspnea occurred in 20.6% of patients during 1 month of DAPT with ticagrelor after PCI for AMI. Again, distinct clinical characteristics were independently associated with dyspnea, e.g., older age, male gender, previous history of asthma, stroke, or previous heart failure. Adherence to ticagrelor in the continuation arm was more affected by dyspnea compared with the clopidogrel de-escalation arm. Early de-escalation to clopidogrel was associated with a greater reduction in the rate of subsequent dyspnea among patients who experienced dyspnea during the initial month of DAPT with ticagrelor. In consistence with previous analyses, the presence of dyspnea at randomization was not associated with increased risk of major adverse cardiac events, bleeding events (Bleeding Academic Research Consortium type 2, 3, or 5), or worse net clinical outcome (p = 0.84). The effect of DAPT de-escalation on clinical outcomes was consistent regardless of the presence or absence of dyspnea, without significant interaction.

The current analysis has limitation due to its post-hoc character, due to significant inter-group differences between patients with and without dyspnea (e.g., poorer left ventricular function, higher prevalence of asthmatic disease) and due to self-reporting of dyspnea without objective confirmation by pulmonary function testing. Therefore, no conclusion can be drawn with regard to the true causal relationship of dyspnea to ticagrelor treatment. Dyspnea was only assessed after 1 month of treatment and pre-existing dyspnea was not evaluated making it hard to assign effects to ticagrelor treatment only.

Some findings are surprising and contradictory to previous observations. First, the prevalence of reported dyspnea was very high for an Asian cohort, approximately 10 times higher compared with previous and contemporary studies that reported much lower incidence rates in Asian populations.[4] [6] [7] Second, the prevalence of nonsmokers was higher among patients with dyspnea; however, smoking status did increase likelihood of dyspnea in particular leading to discontinuation of ticagrelor.[3] Of note, dyspnea declined over time in both the ticagrelor continuation and the clopidogrel de-escalation arm, although the effect was more pronounced in the latter group. Thus, a certain habituation effect and time-dependent effects influencing dyspnea independent of drug therapy play an additional and possibly underestimated role.

Nevertheless, it confirms previous observations regarding the clinical impact of ticagrelor-associated dyspnea. The safe and potentially beneficial aspect of de-escalation therapy 1 to 3 months after AMI/PCI found in several recent trials[8] seem to be consistent in patients who experienced dyspnea under ticagrelor. Thus, de-escalation might represent a reasonable strategy in patients' groups who are likely to develop dyspnea and consequently are at risk for drug discontinuation, e.g., elderly patients who may also benefit by a reduction of bleeding events by early switching to clopidogrel.[9]

However, more evidence is needed to elucidate causal relationships and the true impact of de-escalation or swopping strategies in these patients, with different antithrombotic regimes and patient populations, including different ethnic groups.[10] [11] One systematic review showed that in East Asians, the reduction of DAPT intensity or duration can minimize bleeding, without safety concerns; however, in non-Asians, reduction of DAPT intensity may increase ischemic events, while DAPT abbreviation had no overall benefit.[10]

A dedicated trial to evaluate different concepts including measures to improve adherence by patient education and alternative concepts of de-escalation including ticagrelor dose reduction is highly warranted.

Publikationsverlauf

Eingereicht: 19. September 2024

Angenommen: 20. September 2024

Accepted Manuscript online:
23. September 2024

Artikel online veröffentlicht:
26. November 2024

• References

• 1 Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea?. Thromb Haemost 2012; 108 (06) 1031-1036
• 2 Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014; 63 (23) 2503-2509
• 3 Storey RF, Becker RC, Harrington RA. et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; 32 (23) 2945-2953
• 4 Angiolillo DJ, Cao D, Sartori S. et al. Dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention. JACC Cardiovasc Interv 2023; 16 (20) 2514-2524
• 5 Kim SH, Shin S, Choo EH. et al; TALOS-AMI investigators. Clinical impact of dyspnea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction. Thromb Haemost 2024; 124 (12) 1152-1161
• 6 Ge Z, Kan J, Gao X. et al; ULTIMATE-DAPT investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet 2024; 403 (10439): 1866-1878
• 7 Kim BK, Hong SJ, Cho YH. et al; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020; 323 (23) 2407-2416
• 8 Kang J, Rizas KD, Park KW. et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J 2023; 44 (15) 1360-1370
• 9 Gimbel M, Qaderdan K, Willemsen L. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 2020; 395 (10233): 1374-1381
• 10 Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (08) 773-792
• 11 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432